Smad4 and Eomes converge on a shared transcriptional program associated with inflammatory CD8 T-cell differentiation - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Smad4 and Eomes Interact in a Common Transcriptional Pathway Linked to Inflammatory CD8 T-Cell Differentiation

  • By

  • Karthik Chandiran

  • Nandu C. Karingari

  • Srineeharika Sirigineedi

  • Linda S. Cauley

  • August 17, 2026

Share

Smad4 and Eomes Interact in a Common Transcriptional Pathway

Overview

This study investigates the roles of Smad4 and Eomes in CD8 T cell differentiation, revealing their interaction in regulating gene expression crucial for T cell identity and function. The findings highlight the distinct and overlapping pathways influenced by these transcription factors, particularly in the context of tissue-resident memory T cells.

Background

Transcription factors like Smad4 and Eomes are key regulators in the differentiation of CD8 T cells, influencing T cell fate and functionality. Disruptions in their pathways can lead to impaired immune responses.

Data Highlights

No numerical data or trial data available in the source material.

Key Findings

  • Smad4 and Eomes regulate overlapping and unique gene expression programs in CD8 T cells.
  • Both transcription factors are essential for the differentiation of memory T cells, particularly tissue-resident memory (TRM) cells.
  • Canonical TGF-beta signaling remains active in the absence of Smad4 or Eomes, becoming inactive only when both Smad3 and Smad4 are absent.
  • CD8 T cells lacking both Smad3 and Smad4 show greater enrichment of TRM signature genes compared to those deficient in either factor.
  • Smad4 promotes differentiation of KLRG1+ effector cells while inhibiting TRM cell formation.

Clinical Implications

Understanding the interactions between Smad4 and Eomes could inform strategies to manipulate T cell differentiation.

Conclusion

The interaction between Smad4 and Eomes is critical for CD8 T cell differentiation.

Related Resources & Content

  1. Blood Cancer Journal, Targeting the Inflammasome for Therapy in Myeloid Cancers, 2021
  2. Frontiers in Immunology, PRDM1-mediated epigenetic and transcriptional repression mechanisms, 2026
  3. Frontiers in Immunology, Dynamic activation of lytic cell death-related programs, 2026
  4. Archives of Toxicology, Influence of microRNAs on the response to cadmium chloride, 2021
  5. SMAD signaling in cancer: integrative roles in tumor progression, immune evasion, and therapeutic resistance, ScienceDirect
  6. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols, 2025
  7. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection, PubMed
  8. Mechanistic work on TGF-β/SMAD signaling and CD8 T-cell fate
  9. Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols
  10. EASL Clinical Practice Guidelines on the management of hepatitis B virus infection - PubMed

Original Source(s)

Related Content